mProX™ Human OPRD1 Stable Cell Line

Product Information

Target Protein

OPRD1

Target Family

Opioid Family

Target Protein Species

Rat

Host Cell Type

PC12h;CHO-K1;HEK293

Target Classification

GPCR Cell Lines

Target Research Area

Pain and Addiction Research

Related Diseases

Morphine Dependence;Heroin Dependence

Gene ID

Rat: 24613

UniProt ID

Rat: P33533

Product Properties

Biosafety Level

Level 1

Activity

Yes

Quantity

10⁶ cells per vial

Applications

The OPRD1 gene encodes the delta opioid receptor, which is one of the three major types of opioid receptors in the central nervous system. This receptor plays a significant role in pain perception, mood regulation, and reward mechanisms. Recent studies have highlighted the association of OPRD1 polymorphisms with opioid addiction and its potential role in modulating synaptic plasticity. Additionally, research has shown that OPRD1 is involved in the treatment response of certain medications, suggesting its importance in personalized medicine approaches.

Protocols

Please visit our protocols page.

Customer Reviews

There are currently no Customer reviews or questions for mProX™ Human OPRD1 Stable Cell Line (S01YF-0923-PY151). Click the button above to contact us or submit your feedback about this product.

FAQ

chat Jason (Verified Customer)

Are there any known roles of OPRD1 in programmed cell death? Jul 05 2023

chat Patrick Liam (Creative Biolabs Scientific Support)

Direct associations between OPRD1 and programmed cell death aren't explicitly mentioned. However, proteins like Bcl-2, localized to the inner mitochondrial membrane, have been known to interfere with programmed cell death. Jul 05 2023

chat Laura (Verified Customer)

What are the potential applications of OPRD1 in tumor cell line research? May 17 2020

chat Patrick Liam (Creative Biolabs Scientific Support)

While the direct applications of OPRD1 in tumor cell line research aren't specified in the provided articles, extracellular vesicles from certain cell lines have shown broad and potent anti-tumor activity. May 17 2020

Published Data

Fig.1 Knockdown of Oprd1 in PC12h cells.

NGF expression in PC12h cells was investigated through RT-PCR analysis after a 72-hour treatment with DADLE, subsequent to silencing the Oprd1 gene. Cells were transfected with a combination of three Oprd1 (dor) siRNAs (500 nM each) and one scrambled siRNA (1.5 μM). Following transfection, 0.5 or 0.8 million cells were cultured in 60-mm dishes with 100 ng/mL NGF for 72 hours in the presence or absence of 10 nM DADLE. After this period, the cells were collected for total RNA extraction, and reverse transcription was performed using 2 μg of total RNA per sample, followed by PCR analysis. The resulting PCR products were electrophoresed on a 3% agarose gel and visualized with ethidium bromide staining.

Ref:

Pubmed: 24152443

DOI: 10.3390/ijms141021114

Research Highlights

Yu J, et al. "Methylation and expression quantitative trait loci rs1799971 in the OPRM1 gene ." Neuroscience letters, 2023.
In this study, researchers investigated the role of genetic factors in opioid use disorder (OUD), a chronic and relapsing brain disease that has a significant impact on global mortality. Specifically, the study focused on polymorphisms of opioid receptor genes and how these variations may contribute to the development and characteristics of OUD. The researchers examined methylation levels in the promoter region of three opioid receptor genes and identified single nucleotide polymorphisms (SNPs) associated with both methylation levels and gene expression. They then analyzed the relationship between these SNPs and OUD susceptibility and characteristics in a group of healthy controls and patients with OUD. The results showed that certain SNPs were both methylation quantitative trait loci (mQTLs) and expression quantitative trait loci (eQTLs). Furthermore, unique correlations were found between these mQTLs and methylation levels in the OUD group compared to healthy controls. The mQTLs and eQTLs were also found to be associated with OUD susceptibility. The study suggests that these mQTLs and eQTLs may play a role in the link between specific genetic polymorphisms and OUD and could potentially serve as biomarkers for the management of opioid misuse.
Pubmed: 37660978 DOI: 10.1016/j.neulet.2023.137468

Peles E, et al. "Predictors of treatment retention and survival among methadone-maintained ." Drug and alcohol dependence, 2023.
The study aimed to examine the potential association between variants in the OPRD1 gene and opioid use disorder, as well as response to treatment. Data from 488 patients undergoing methadone maintenance treatment (MMT) from June 1993 to June 2022 were analyzed to determine predictors of retention and survival time. Results showed that carriers of the T allele of the SNP rs204076, associated with OPRD1 expression in the cortex, had longer retention (11.2 vs. 8.8 years) and survival (24.7 vs. 20.2 years). Multivariate analysis identified the T allele as an independent predictor of longer retention and survival. Other factors that contributed to longer retention included no benzodiazepine use after one year in MMT, no hepatitis C, and younger age at admission. Findings suggest that both genetic and non-genetic factors play a role in survival and retention among MMT patients.
Pubmed: 37531661 DOI: 10.1016/j.drugalcdep.2023.110903